Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FEBUXOSTAT vs ALOPRIM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Febuxostat is a non-purine selective inhibitor of xanthine oxidase (XO). It inhibits both oxidized and reduced forms of XO, thereby reducing the conversion of hypoxanthine to xanthine and xanthine to uric acid, leading to decreased serum uric acid levels.
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations.
Chronic management of hyperuricemia in patients with gout,Off-label: Prevention of tumor lysis syndrome,Off-label: Management of hyperuricemia in kidney transplant recipients
FDA-approved: Management of hyperuricemia in gout, management of hyperuricemia in patients with recurrent uric acid stones, and prevention of tumor lysis syndrome in patients receiving chemotherapy.,Off-label: Prevention of calcium oxalate calculi, management of hyperuricemia in patients with renal impairment, and treatment of Lesch-Nyhan syndrome.
40 mg orally once daily; may increase to 80 mg orally once daily if serum urate goal not achieved after 2 weeks.
300 mg orally once daily; may be increased to 600-800 mg/day in divided doses for severe gout.
Terminal elimination half-life: 5-8 hours in healthy subjects; prolonged in renal impairment (e.g., up to 9.6 hours in moderate impairment). Clinical context: dosing interval is once daily, consistent with half-life.
Allopurinol: 1-2 h; Oxypurinol: 18-30 h (prolonged in renal impairment, up to 7 days in severe CKD)
Primarily metabolized by conjugation via UDP-glucuronosyltransferases (UGT1A1, UGT1A3, UGT1A9, and UGT2B7) and oxidation via cytochrome P450 (CYP) enzymes, including CYP1A2, CYP2C8, and CYP2C9, with minor contribution from CYP3A4/5.
Allopurinol is metabolized primarily by xanthine oxidase to its active metabolite, oxypurinol. Both allopurinol and oxypurinol are further metabolized to a lesser extent by aldehyde oxidase.
Renal: 1-3% unchanged; biliary/fecal: ~50% as metabolites (acyl glucuronides, oxidative metabolites); other: ~49% metabolized and eliminated via multiple pathways including biliary and direct intestinal excretion of unchanged drug.
Renal: ~70% (30% as allopurinol, 40% as oxypurinol); fecal: ~20%; biliary: minor (<5%)
99% (primarily to albumin; minor binding to alpha-1-acid glycoprotein).
Allopurinol: <1%; Oxypurinol: ~20% (primarily to albumin)
Approximately 0.7 L/kg (indicating distribution into total body water; not extensively tissue-bound).
Allopurinol: 0.6-1.6 L/kg (suggests distribution in total body water); Oxypurinol: 0.6-1.0 L/kg
Oral: at least 49% (absolute bioavailability not established; estimated based on mass balance studies).
Oral: 67-90% (allopurinol); rapidly converted to oxypurinol
No dose adjustment required for mild to moderate renal impairment (e GFR 30-89 m L/min). For severe renal impairment (e GFR <30 m L/min), limited data; use with caution, not recommended in dialysis.
GFR 30-60 m L/min: start at 200 mg/day; GFR 10-29 m L/min: 100 mg/day; GFR <10 m L/min: 100 mg every other day or 50 mg/day.
Child-Pugh Class A or B: no dose adjustment. Child-Pugh Class C: not recommended (no studies).
No specific adjustment recommended; use with caution in severe hepatic impairment.
Not approved for pediatric use; safety and efficacy not established.
Children 10-20 mg/kg/day in 2-3 divided doses, maximum 400 mg/day.
No specific dose adjustment required; use with caution due to potential for decreased renal function.
Initiate at lower doses (e.g., 100 mg/day) due to age-related renal decline; monitor for adverse effects.
Increased risk of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent revascularization in patients with established cardiovascular disease (based on the CARES trial). Febuxostat should be avoided in patients with a history of myocardial infarction or stroke, unless no other therapy is appropriate.
Allopurinol has been associated with hypersensitivity reactions including severe skin reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening. The risk is higher in patients with renal impairment and those receiving thiazide diuretics. Discontinue at first sign of rash or other signs of hypersensitivity.
Cardiovascular events (see black box warning); hepatotoxicity (elevated liver enzymes, hepatic failure); gout flares upon initiation (prophylaxis recommended); renal impairment (dose adjustment for severe impairment); hypersensitivity reactions (including Stevens-Johnson syndrome); thyroid function abnormalities (elevated TSH).
Risk of severe hypersensitivity reactions including SJS/TEN; increased risk in patients with renal impairment or concomitant thiazide use. Monitor for rash. Acute gout attacks may increase during early therapy; prophylaxis with colchicine or NSAIDs is recommended. Hepatic and renal function should be monitored. May cause drowsiness or dizziness.
Concurrent use with azathioprine, 6-mercaptopurine, or theophylline (due to risk of toxicity); severe renal impairment (Cr Cl <30 m L/min) based on trial data; history of myocardial infarction or stroke (relative contraindication per FDA).
Absolute: Patients with a history of a severe hypersensitivity reaction to allopurinol. Relative: Renal impairment (dose adjustment needed), pregnancy (only if benefit outweighs risk), and lactation (use caution).
No specific food interactions are reported, but high-purine foods (red meat, organ meats, shellfish) and alcohol may increase serum urate and counteract drug efficacy; advise moderation and limit intake during therapy.
Avoid high-purine foods (e.g., organ meats, anchovies, sardines, mussels, scallops, red meat, beer) as they may increase serum uric acid levels and reduce drug efficacy. Maintain adequate hydration to prevent urate nephropathy. Grapefruit juice has no known interaction. No significant interaction with caffeine.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, febuxostat caused developmental toxicity (reduced fetal weight, increased skeletal variations) at maternal toxic doses. First trimester: unknown risk; avoid unless benefits outweigh risks. Second/third trimester: limited data; potential for fetal harm based on animal findings.
First trimester: No evidence of teratogenicity in humans; animal studies show no fetal harm. Second/third trimester: No known risks; allopurinol crosses placenta but no congenital anomalies reported. Postnatal: No adverse effects reported.
Excretion in human milk unknown; M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy.
Allopurinol and its metabolite oxypurinol are excreted in breast milk; M/P ratio not established. No adverse effects reported in nursing infants. Use with caution, especially in infants with G6PD deficiency.
No specific pharmacokinetic data in pregnancy. Due to potential teratogenicity, avoid in pregnancy. If use is unavoidable, no dose adjustment studies exist; use lowest effective dose with caution.
No dose adjustment required based on pregnancy alone. However, dose may need adjustment if renal function declines. Allopurinol pharmacokinetics not significantly altered in pregnancy; maintain dose based on renal function and uric acid levels.
Febuxostat is a non-purine selective xanthine oxidase inhibitor indicated for chronic management of hyperuricemia in gout. It is contraindicated with concomitant azathioprine, mercaptopurine, or theophylline due to risk of toxicity. Initiate at 40 mg daily; titrate to 80 mg if serum urate not at target after 2 weeks. Monitor for gout flares during initiation; provide prophylactic NSAIDs or colchicine for at least 6 months. Cardiovascular risk: increased risk of cardiovascular death vs allopurinol in patients with history of CV disease; avoid as first-line or in patients with prior MI or stroke. Assess liver function tests at baseline and periodically; discontinue if persistent elevation >3x ULN or signs of liver injury. Not recommended in patients with severe hepatic impairment (Child-Pugh C).
Initiate therapy after acute gout flare has subsided; consider gradual dose titration to reduce flare risk; monitor for hypersensitivity reactions, especially in patients with renal impairment; use with caution in patients on thiazide diuretics or ACE inhibitors due to increased risk of hypersensitivity; assess renal function before starting and during therapy; adjust dose in renal impairment (Cr Cl <60 m L/min); avoid use with azathioprine or mercaptopurine unless dose reduction of these agents is implemented; educate patient to report rash, fever, or lymphadenopathy immediately.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,You may experience gout flares during the first few months; continue your medication and take prescribed anti-inflammatory drugs as directed.,Report any signs of heart attack or stroke (chest pain, shortness of breath, weakness on one side of body, slurred speech) immediately.,Avoid alcohol, especially beer, which can increase uric acid levels and trigger gout flares.,Inform your doctor if you are taking azathioprine, mercaptopurine, or theophylline; these are not safe to take with febuxostat.,If you have a history of heart attack, stroke, or heart disease, discuss alternative treatments with your doctor.,Seek medical attention for signs of liver injury (yellow skin/eyes, dark urine, abdominal pain, persistent nausea).,Stay hydrated to help prevent kidney stones; aim for 8-10 glasses of water daily unless otherwise advised.,Do not crush or chew tablets; swallow whole with water.
Take this medication exactly as prescribed, usually once daily.,Do not start or stop taking this medication during an acute gout attack; wait until the flare has resolved.,Drink plenty of fluids (at least 2 liters of water per day) unless otherwise directed by your doctor.,Avoid alcohol and foods high in purines (e.g., red meat, organ meats, shellfish) as they may increase uric acid levels.,Report any skin rash, itching, swelling, or difficulty breathing to your doctor immediately.,Inform your doctor of all medications you are taking, including over-the-counter drugs and supplements.,Do not take this medication with azathioprine, mercaptopurine, or theophylline unless specifically instructed by your doctor.,Store at room temperature away from moisture and heat.
"Mercaptopurine is metabolized by xanthine oxidase. Febuxostat inhibits xanthine oxidase, leading to significantly reduced clearance of mercaptopurine and its active metabolites. This can result in severe myelosuppression, including life-threatening neutropenia and thrombocytopenia, as well as hepatotoxicity."
"The serum concentration of the active metabolites of Aminophylline can be increased when Aminophylline is used in combination with Febuxostat."
"The serum concentration of Febuxostat can be increased when it is combined with Azathioprine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FEBUXOSTAT vs ALOPRIM, answered by our medical review team.
FEBUXOSTAT is a Xanthine Oxidase Inhibitor that works by Febuxostat is a non-purine selective inhibitor of xanthine oxidase (XO). It inhibits both oxidized and reduced forms of XO, thereby reducing the conversion of hypoxanthine to xanthine and xanthine to uric acid, leading to decreased serum uric acid levels.. ALOPRIM is a Xanthine Oxidase Inhibitor that works by Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FEBUXOSTAT and ALOPRIM depend on the specific clinical indication. These are both Xanthine Oxidase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FEBUXOSTAT is: 40 mg orally once daily; may increase to 80 mg orally once daily if serum urate goal not achieved after 2 weeks.. The standard adult dose of ALOPRIM is: 300 mg orally once daily; may be increased to 600-800 mg/day in divided doses for severe gout.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FEBUXOSTAT and ALOPRIM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FEBUXOSTAT is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, febuxostat caused developmental toxicity (reduced fetal weight, increased skeletal variations) at ma. ALOPRIM is classified as Category C. First trimester: No evidence of teratogenicity in humans; animal studies show no fetal harm. Second/third trimester: No known risks; allopurinol crosses placenta but no congenital . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.